Business, energy, technology, markets and global industry news from Business News Today

COPD

PharmaDeviceNews COPD
Representative image: Respiratory medicine deal discussion highlighting Sino Biopharmaceutical’s AstraZeneca TQC3721 licensing agreement and expanded GSK inhaler commercialization rights in China.
Pharma & Biotech

Why Sino Biopharmaceutical’s twin respiratory deals may worry global pharma rivals

Sino Biopharmaceutical Limited has secured two respiratory medicine transactions involving AstraZeneca PLC and GSK plc, strengthening both its out-licensing and China commercialization strategy. Its subsidiary Chia Tai Tianqing Pharmaceutical Group granted AstraZeneca exclusive rights outside China to develop, manufacture and commercialize TQC3721, an investigational PDE3/4 inhibitor for chronic respiratory disease, while separately obtaining mainland China

Read More
Representative image: A nebulized respiratory therapy setup illustrates the clinical focus behind AeroRx Therapeutics’ AERO-007 Phase 2a COPD data, as researchers evaluate whether once-daily LABA+LAMA nebulized treatment can address persistent delivery challenges in chronic obstructive pulmonary disease care.
Pharma & Biotech

Can AeroRx turn nebulized COPD treatment into a first-line dual bronchodilator category?

COPD care relies on handheld inhalers, but many patients struggle with delivery. AeroRx is testing whether nebulized dual therapy can close that gap.

Read More
Representative image of an inhaler used in asthma and COPD treatment. GSK’s Trelegy Ellipta has become the first approved single inhaler triple therapy for both conditions in China.
Pharma & Biotech

GSK’s Trelegy Ellipta becomes China’s first approved triple therapy for both asthma and COPD

GSK plc has received regulatory approval from China’s National Medical Products Administration (NMPA) to market Trelegy Ellipta, a once-daily inhaled combination of fluticasone furoate, umeclidinium, and vilanterol, for the treatment of adult patients with uncontrolled asthma. This decision expands Trelegy Ellipta’s label beyond its existing indication in chronic obstructive pulmonary disease (COPD), making it the

Read More
Pharma & Biotech

AirNexis launches with $200m and Phase 2 dual PDE3/4 COPD drug licensed from Haisco

AirNexis launches with $200M and ex-China rights to AN01. Find out why this dual-pathway COPD therapy is drawing investor attention in 2026.

Read More
Representative image illustrating the rising focus on U.S. drug pricing reform, as pharmaceutical companies like GSK move to expand access to asthma and COPD medicines through lower costs and direct purchasing models.
Pharma & Biotech

GSK strikes deal with U.S. to lower asthma and COPD drug prices and avoid tariffs

GSK plc’s latest agreement with the United States Administration to lower the price of respiratory medicines, including its inhaled asthma and chronic obstructive pulmonary disease (COPD) portfolio, signals a shift in how global pharmaceutical companies are choosing to respond to increasing U.S. political pressure around drug affordability. The agreement, announced on December 22, 2025, satisfies

Read More
Representative image: Chronic obstructive pulmonary disease lung inflammation and airway damage, illustrating the disease context targeted by emerging biologic therapies such as Mabwell’s anti‑ST2 antibody 9MW1911 in clinical development.
Pharma & Biotech

Mabwell’s anti-ST2 antibody 9MW1911 cleared for U.S. Phase IIa trial: Could this reshape COPD biologics?

Mabwell Biopharmaceuticals has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration to initiate a Phase IIa clinical study for its anti-ST2 monoclonal antibody, 9MW1911, in patients with moderate-to-severe chronic obstructive pulmonary disease. This regulatory milestone comes on the heels of a completed Phase IIa study in China, where Mabwell

Read More